| 1 |
rituximab
(1220 times)
|
Rheumatology
(318 times)
|
RA (148 times)
CYC (68 times)
ANCA (63 times)
|
2002 Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion.
|
| 2 |
resiniferatoxin
(373 times)
|
Neurology
(108 times)
|
TRPV1 (89 times)
DRG (41 times)
CGRP (22 times)
|
1989 Duration of desensitization and ultrastructural changes in dorsal root ganglia in rats treated with resiniferatoxin, an ultrapotent capsaicin analog.
|
| 3 |
repeats-in-toxin
(119 times)
|
Biochemistry
(31 times)
|
LFA-1 (7 times)
HlyA (6 times)
ACT (4 times)
|
1994 Identification and immunological characterization of the domain of Actinobacillus actinomycetemcomitans leukotoxin that determines its specificity for human target cells.
|
| 4 |
raltitrexed
(41 times)
|
Neoplasms
(19 times)
|
TS (18 times)
5-FU (9 times)
OXA (4 times)
|
1998 Modeling of the time-dependency of in vitro drug cytotoxicity and resistance.
|
| 5 |
response to rituximab
(25 times)
|
Rheumatology
(15 times)
|
RA (14 times)
EULAR (7 times)
RF (5 times)
|
2008 NK and NKT cell dynamics after rituximab therapy for systemic lupus erythematosus and rheumatoid arthritis.
|
| 6 |
response to treatment with rituximab
(5 times)
|
Rheumatology
(2 times)
|
DMTs (1 time)
EULAR (1 time)
FcgammaR (1 time)
|
2011 Identification of patients with indolent B cell lymphoma sensitive to rituximab monotherapy.
|
| 7 |
received treatment with rituximab
(4 times)
|
Eye Diseases
(2 times)
|
AAR (1 time)
IQR (1 time)
NMOSD (1 time)
|
2020 Effect of rituximab on disease activity in latin American patients with anti-aquaporin-4 (+) neuromyelitis optica spectrum disorder.
|
| 8 |
repeat toxin
(4 times)
|
Communicable Diseases
(2 times)
|
VSP (2 times)
|
1992 Separable domains define target cell specificities of an RTX hemolysin from Actinobacillus pleuropneumoniae.
|
| 9 |
repeats in the structural toxin
(4 times)
|
Veterinary Medicine
(2 times)
|
cDNA (1 time)
PCR (1 time)
|
2001 Cloning and characterization of a Moraxella bovis cytotoxin gene.
|
| 10 |
Repeat-in-Toxins
(3 times)
|
Molecular Biology
(2 times)
|
---
|
2012 Backbone resonance assignments of the outer membrane lipoprotein FrpD from Neisseria meningitidis.
|
| 11 |
reported the efficacy of rituximab
(3 times)
|
Rheumatology
(2 times)
|
ANCA (1 time)
BVAS (1 time)
CRP (1 time)
|
2013 Experiences with rituximab for the treatment of autoimmune diseases with ocular involvement.
|
| 12 |
re-treated with rituximab
(2 times)
|
Arthritis
(2 times)
|
AAV (1 time)
AZA (1 time)
CYC (1 time)
|
2013 Usefulness of power Doppler ultrasound for prediction of re-therapy with rituximab in rheumatoid arthritis: a prospective study of longstanding rheumatoid arthritis patients.
|
| 13 |
regarding the use of Rituximab
(2 times)
|
Nephrology
(1 time)
|
CR (1 time)
FCR (1 time)
MCNS (1 time)
|
2020 Retrospective single-arm cohort study of steroid-dependent minimal change nephrotic syndrome treated with very low-dose rituximab.
|
| 14 |
reported that rituximab
(2 times)
|
Allergy and Immunology
(2 times)
|
CAMR (1 time)
DeltaeGFR (1 time)
HC (1 time)
|
2008 Binding of rituximab, trastuzumab, cetuximab, or mAb T101 to cancer cells promotes trogocytosis mediated by THP-1 cells and monocytes.
|
| 15 |
ruthenium tetroxide
(2 times)
|
Jurisprudence
(2 times)
|
CA (1 time)
|
2004 Evaluation of iodine-benzoflavone and ruthenium tetroxide spray reagents for the detection of latent fingermarks at the crime scene.
|
| 16 |
131I-rituximab
(1 time)
|
Neoplasms
(1 time)
|
DIA (1 time)
RA (1 time)
RIT (1 time)
|
2022 Diacerein, an inhibitor of IL-1beta downstream mediated apoptosis, improves radioimmunotherapy in a mouse model of Burkitt's lymphoma.
|
| 17 |
dose-rituximab
(1 time)
|
Hematology
(1 time)
|
AIHA (1 time)
NHL (1 time)
|
2012 Incipient Coombs' test negative autoimmune hemolytic anemia precedes non-Hodgkin's lymphoma.
|
| 18 |
RA treated with B-lymphocytedepletive rituximab
(1 time)
|
|
a-CCP (1 time)
a-MCV (1 time)
ACPA (1 time)
|
2010 Serum levels of anti-CCP antibodies, anti-MCV antibodies and RF IgA in the follow-up of patients with rheumatoid arthritis treated with rituximab.
|
| 19 |
randomized to receive either rituximab
(1 time)
|
Arthritis
(1 time)
|
AAV (1 time)
AZA (1 time)
CYC (1 time)
|
2014 Peripheral CD5+ B cells in antineutrophil cytoplasmic antibody-associated vasculitis.
|
| 20 |
Rapid Thermal Exchange
(1 time)
|
Physical Fitness
(1 time)
|
HR (1 time)
Tc (1 time)
|
2009 Is performance of intermittent intense exercise enhanced by use of a commercial palm cooling device?
|
| 21 |
rapid thermal exchange device
(1 time)
|
Sports Medicine
(1 time)
|
HR (1 time)
WB (1 time)
WPV (1 time)
|
2010 Palm cooling does not reduce heat strain during exercise in a hot, dry environment.
|
| 22 |
Rapid Thermal Exchange System
(1 time)
|
Sports Medicine
(1 time)
|
HR (1 time)
RPE (1 time)
Tc (1 time)
|
2015 The effect of hand cooling during intermittent training of elite swimmers.
|
| 23 |
rats treated with resiniferatoxin
(1 time)
|
Medicine
(1 time)
|
HFD (1 time)
WAT (1 time)
|
2014 Capsaicin induces "brite" phenotype in differentiating 3T3-L1 preadipocytes.
|
| 24 |
re-exposed to rituximab
(1 time)
|
Immune System Diseases
(1 time)
|
GC (1 time)
MBCs (1 time)
RA (1 time)
|
2022 Persistent but atypical germinal center reaction among 3rd SARS-CoV-2 vaccination after rituximab exposure.
|
| 25 |
Real-time eXtended
(1 time)
|
Biosensing Techniques
(1 time)
|
RMS (1 time)
RTK (1 time)
|
2022 Performance Evaluation of GNSS Position Augmentation Methods for Autonomous Vehicles in Urban Environments.
|
| 26 |
real-world, long-term effectiveness of rituximab
(1 time)
|
Rheumatology
(1 time)
|
IS (1 time)
PFTs (1 time)
RA-ILD (1 time)
|
2020 Real-world clinical effectiveness of rituximab rescue therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease.
|
| 27 |
received the first rituximab
(1 time)
|
Urologic Diseases
(1 time)
|
ACEi (1 time)
|
2014 Immunoadsorption: a new strategy to induce remission in membranous lupus nephritis.
|
| 28 |
Recently the use of rituximab
(1 time)
|
Nephrology
(1 time)
|
MN (1 time)
PLA2R (1 time)
pts (1 time)
|
2020 Efficacy of low or standard rituximab-based protocols and comparison to Ponticelli's regimen in membranous nephropathy.
|
| 29 |
reduces the accessibility of rituximab
(1 time)
|
Clinical Laboratory Techniques
(1 time)
|
CNS (1 time)
MTX (1 time)
|
2010 Schedule-dependent synergistic effect of rituximab on methotrexate chemotherapy against lymphoma of the central nervous system.
|
| 30 |
related to resiniferatoxin
(1 time)
|
|
---
|
2013 Resiniferatoxin for Pain Treatment: An Interventional Approach to Personalized Pain Medicine.
|
| 31 |
related to rituximab
(1 time)
|
Pharmacology
(1 time)
|
---
|
2011 [Ulcerative colitis: exceptional consequence after rituximab therapy].
|
| 32 |
repeat treatment regimens of rituximab
(1 time)
|
Rheumatology
(1 time)
|
EULAR (1 time)
|
2010 Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: results of a Phase III randomized study (MIRROR).
|
| 33 |
repeat-in-toxin family
(1 time)
|
Medical Informatics
(1 time)
|
A. actinomycetemcomitans (1 time)
|
2022 Computational modeling and druggability assessment of Aggregatibacter actinomycetemcomitans leukotoxin.
|
| 34 |
repeats in structural toxin genes
(1 time)
|
Allergy and Immunology
(1 time)
|
---
|
2000 Legionella pneumophila entry gene rtxA is involved in virulence.
|
| 35 |
repeats in the toxin
(1 time)
|
Molecular Biology
(1 time)
|
CTX (1 time)
PCR (1 time)
TLC (1 time)
|
2014 Construction and characterization of a Vibrio cholerae serogroup O139 vaccine candidate by genetic engineering.
|
| 36 |
repeats-in-toxin domain
(1 time)
|
Allergy and Immunology
(1 time)
|
ACT (1 time)
wP (1 time)
|
2018 Evaluation of Adenylate Cyclase Toxoid Antigen in Acellular Pertussis Vaccines by Using a Bordetella pertussis Challenge Model in Mice.
|
| 37 |
report two cases of rituximab
(1 time)
|
Medicine
(1 time)
|
---
|
2015 [Rituximab-induced interstitial pneumonitis: report of two cases and literature review].
|
| 38 |
reporting the outcome of rituximab
(1 time)
|
Nephrology
(1 time)
|
FSGS (1 time)
MCD (1 time)
|
2014 Rituximab treatment for relapsing minimal change disease and focal segmental glomerulosclerosis: a systematic review.
|
| 39 |
resistant to rituximab
(1 time)
|
Neoplasms
(1 time)
|
ALL (1 time)
ALM (1 time)
CDC (1 time)
|
2015 Neutralization of membrane complement regulators improves complement-dependent effector functions of therapeutic anticancer antibodies targeting leukemic cells.
|
| 40 |
resource taxes
(1 time)
|
Environmental Health
(1 time)
|
FIT (1 time)
FSB (1 time)
REC (1 time)
|
2022 The Effectiveness and Trade-Offs of Renewable Energy Policies in Achieving the Dual Decarbonization Goals in China: A Dynamic Computable General Equilibrium Analysis.
|
| 41 |
respond to conventional therapy, rituximab
(1 time)
|
Dermatology
(1 time)
|
MMP (1 time)
|
2012 Critical analysis of the use of rituximab in mucous membrane pemphigoid: a review of the literature.
|
| 42 |
response to raltitrexed
(1 time)
|
Neoplasms
(1 time)
|
DPD (1 time)
TP (1 time)
TS (1 time)
|
2003 Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.
|
| 43 |
Response to Unilateral Periganglionic Resiniferatoxin
(1 time)
|
Pain
(1 time)
|
---
|
2020 Response to "Unilateral Periganglionic Resiniferatoxin (RTX) for Personalized Pain Treatment".
|
| 44 |
responsiveness to rituximab
(1 time)
|
Rheumatology
(1 time)
|
RA (1 time)
TBG (1 time)
|
2020 Fetuin-A and thyroxin binding globulin predict rituximab response in rheumatoid arthritis patients with insufficient response to anti-TNFalpha.
|
| 45 |
revealed that robustoxin
(1 time)
|
Toxicology
(1 time)
|
TTX-R (1 time)
TTX-S (1 time)
VTX (1 time)
|
1996 Selective alteration of sodium channel gating by Australian funnel-web spider toxins.
|
| 46 |
reverse transcription xenopolymerase
(1 time)
|
Science
(1 time)
|
RT (1 time)
|
2016 Synthetic evolutionary origin of a proofreading reverse transcriptase.
|
| 47 |
review the use rituximab
(1 time)
|
Education
(1 time)
|
eGFR (1 time)
GN (1 time)
IgG4-RD (1 time)
|
2022 Use of Rituximab as an Off-Label Medication in Glomerular Diseases: Clinical Perspective.
|
| 48 |
right ventricular Tei index
(1 time)
|
Veterinary Medicine
(1 time)
|
CVs (1 time)
ICCs (1 time)
RTXDPD (1 time)
|
2016 Repeatability and reproducibility of right ventricular Tei index valves derived from three echocardiographic methods for evaluation of cardiac function in dogs.
|
| 49 |
rituximab treatment
(1 time)
|
Allergy and Immunology
(1 time)
|
IGHV (1 time)
pSS (1 time)
|
2014 Ig gene analysis reveals altered selective pressures on Ig-producing cells in parotid glands of primary Sjogren's syndrome patients.
|
| 50 |
Robotic thymectomy via the subxiphoid approach
(1 time)
|
Cardiology
(1 time)
|
---
|
2020 The robotic thymectomy via the subxiphoid approach: technique and early outcomes.
|
| 51 |
RTX group
(1 time)
|
Otolaryngology
(1 time)
|
ANCA (1 time)
GC (1 time)
IVCY (1 time)
|
2018 The treatment outcomes of rituximab for intractable otitis media with ANCA-associated vasculitis.
|
| 52 |
RTX test
(1 time)
|
Natural Science Disciplines
(1 time)
|
i.c.v (1 time)
TRPV1 (1 time)
|
2017 Supraspinal-selective TRPV1 desensitization induced by intracerebroventricular treatment with resiniferatoxin.
|
| 53 |
RTX was acutely applied to the pericardial space in controls
(1 time)
|
Physiology
(1 time)
|
CHF (1 time)
FC (1 time)
MI (1 time)
|
2020 Cardiac sensory afferents modulate susceptibility to anxio-depressive behaviour in a mouse model of chronic heart failure.
|
| 54 |
RTX-5MS
(1 time)
|
Chemistry Techniques, Analytical
(1 time)
|
PCDDs (1 time)
PCDFs (1 time)
|
2001 Liquid crystalline polysiloxane polymer as stationary phase in gas chromatography capillary column for the separation of dioxin/furan compounds.
|
| 55 |
RTX/GO
(1 time)
|
Neoplasms
(1 time)
|
Ab (1 time)
GO (1 time)
NHL (1 time)
|
2016 Association of rituximab with graphene oxide confers direct cytotoxicity for CD20-positive lymphoma cells.
|
A Search Service for Abbreviation / Long Form